Analytical Data
-
Gene name
IFN-zeta/Limitin
- Application
-
Alternative Names
Limitin; IFN-z; BGIF; Ifnz; interferon zeta; Lmtn; IFN-zeta
-
Species
Mouse
-
Source
HEK293
-
Tag
C-6*His
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
Q9R1T0
-
Expression Region
L22-R182
-
Protein Length
Full Length of Mature Protein
-
Molecular Weight
19 kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
IFN-zeta, also known as Limitin, is a member of the interferon (IFN) family, which plays a critical role in the immune response against viral infections and tumors. It is produced primarily by immune cells and has been shown to exhibit antiproliferative and antiviral activities. Research on IFN-zeta has gained momentum due to its unique properties that differ from other IFNs, such as IFN-alpha and IFN-beta. These properties include the ability to enhance the activity of natural killer (NK) cells and modulate the immune response. Recent studies have indicated that IFN-zeta could be a key player in combating chronic viral infections and certain malignancies, as it not only triggers the immune system but also poses less risk of adverse side effects compared to other IFNs. The recombinant protein form of IFN-zeta is of particular interest for therapeutic applications, as it offers the potential to harness its immune-modulating effects in a controlled manner. Additionally, ongoing research aims to elucidate the signaling pathways activated by IFN-zeta, as well as its interactions with other cytokines and immune cells. Understanding the mechanisms underlying IFN-zeta's actions can pave the way for the development of novel immunotherapies that exploit its unique characteristics, particularly for conditions where conventional treatments are lacking efficacy. Thus, the study of IFN-zeta and its recombinant protein form is essential for advancing therapeutic strategies in infectious diseases and cancer, providing hope for improved clinical outcomes.
